Next Article in Journal
Electronic Component Mounting for Durable E-Textiles: Direct Soldering of Components onto Textile-Based Deeply Permeated Conductive Patterns
Previous Article in Journal
On-chip MIC by Combining Concentration Gradient Generator and Flanged Chamber Arrays
Open AccessArticle

Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput

1
Department of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA
2
Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston Salem, NC 27101, USA
3
Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Winston-Salem, NC 27101, USA
4
Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA
5
The Ohio State University Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH 43420, USA
6
Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, NC 27101, USA
7
Comprehensive Cancer Center at Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA
8
Department of Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA
9
Department of Neuroscience, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA
10
Department of Surgery–Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA
*
Author to whom correspondence should be addressed.
The authors contributed equally.
Micromachines 2020, 11(2), 208; https://doi.org/10.3390/mi11020208
Received: 21 January 2020 / Revised: 14 February 2020 / Accepted: 17 February 2020 / Published: 18 February 2020
(This article belongs to the Section B:Biology and Biomedicine)
The current drug development pipeline takes approximately fifteen years and $2.6 billion to get a new drug to market. Typically, drugs are tested on two-dimensional (2D) cell cultures and animal models to estimate their efficacy before reaching human trials. However, these models are often not representative of the human body. The 2D culture changes the morphology and physiology of cells, and animal models often have a vastly different anatomy and physiology than humans. The use of bioengineered human cell-based organoids may increase the probability of success during human trials by providing human-specific preclinical data. They could also be deployed for personalized medicine diagnostics to optimize therapies in diseases such as cancer. However, one limitation in employing organoids in drug screening has been the difficulty in creating large numbers of homogeneous organoids in form factors compatible with high-throughput screening (e.g., 96- and 384-well plates). Bioprinting can be used to scale up deposition of such organoids and tissue constructs. Unfortunately, it has been challenging to 3D print hydrogel bioinks into small-sized wells due to well–bioink interactions that can result in bioinks spreading out and wetting the well surface instead of maintaining a spherical form. Here, we demonstrate an immersion printing technique to bioprint tissue organoids in 96-well plates to increase the throughput of 3D drug screening. A hydrogel bioink comprised of hyaluronic acid and collagen is bioprinted into a viscous gelatin bath, which blocks the bioink from interacting with the well walls and provides support to maintain a spherical form. This method was validated using several cancerous cell lines, and then applied to patient-derived glioblastoma (GBM) and sarcoma biospecimens for drug screening. View Full-Text
Keywords: bioprinting; bioink; extracellular matrix; cancer; organoid; drug screening; personalized medicine bioprinting; bioink; extracellular matrix; cancer; organoid; drug screening; personalized medicine
Show Figures

Graphical abstract

MDPI and ACS Style

Maloney, E.; Clark, C.; Sivakumar, H.; Yoo, K.; Aleman, J.; Rajan, S.A.P.; Forsythe, S.; Mazzocchi, A.; Laxton, A.W.; Tatter, S.B.; Strowd, R.E.; Votanopoulos, K.I.; Skardal, A. Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines 2020, 11, 208. https://doi.org/10.3390/mi11020208

AMA Style

Maloney E, Clark C, Sivakumar H, Yoo K, Aleman J, Rajan SAP, Forsythe S, Mazzocchi A, Laxton AW, Tatter SB, Strowd RE, Votanopoulos KI, Skardal A. Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput. Micromachines. 2020; 11(2):208. https://doi.org/10.3390/mi11020208

Chicago/Turabian Style

Maloney, Erin; Clark, Casey; Sivakumar, Hemamylammal; Yoo, KyungMin; Aleman, Julio; Rajan, Shiny A.P.; Forsythe, Steven; Mazzocchi, Andrea; Laxton, Adrian W.; Tatter, Stephen B.; Strowd, Roy E.; Votanopoulos, Konstantinos I.; Skardal, Aleksander. 2020. "Immersion Bioprinting of Tumor Organoids in Multi-Well Plates for Increasing Chemotherapy Screening Throughput" Micromachines 11, no. 2: 208. https://doi.org/10.3390/mi11020208

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop